Pharmaceutical industry news

AspenBio Pharma Advances AppyScore Towards Clinical Trials With ... - FOXBusiness

AspenBio Pharma Advances AppyScore Towards Clinical Trials With ... FOXBusiness - 54 minutes ago Central to completing and filing the FDA 510(k) application is the completion of the clinical trial section, which is planned to involve the testing of ...

Genzyme Reports Strong First-Quarter Growth - FOXBusiness

Genzyme Reports Strong First-Quarter Growth FOXBusiness - 49 minutes ago Mipomersen for high-risk cardiovascular disease Genzyme expects to finalize its license of mipomersen from Isis Pharmaceuticals in the second quarter and ...

can phentermine be taken with vitamins - dBTechno

can phentermine be taken with vitamins dBTechno, MA - 19 hours ago Market, but nowadays about these. No experience in producing these, consider employing an essential small multiples. Margins that profits have except in ...

Cardiac Pacemakers Market to reach .7 billion by 2010, According ... - Emediawire (press release)

Cardiac Pacemakers Market to reach .7 billion by 2010, According ... Emediawire (press release), WA - Apr 21, 2008 ... an aging global population, and the subsequent rise in the incidence of cardiovascular diseases, has ensured a steady growth for the pacemakers market. ...

Neglected diseases - Washington Times

Neglected diseases Washington Times, DC - 2 hours ago By Sam Brownback Tomorrow, World Malaria Day 2008, offers a chance for those of us blessed to live in a nation largely free of entrenched infectious ...

Lupin in the pink of health on overseas expansion plan - NDTV.com

Lupin in the pink of health on overseas expansion plan NDTV.com, India - 32 minutes ago Kyowa Pharmaceutical Industry Co has received approvals for generic variants including hypertension drug amlodipine, schizophrenia drug risperidone and ...

Looking for Life After Lipitor - Wall Street Journal

Looking for Life After Lipitor Wall Street Journal - 34 minutes ago WSJ: How do you think the presidential election could affect the pharmaceutical industry, in light of negativity toward drug companies on the campaign trail ...

Boston Scientific Named Healthcare Supplier of the Year by Global Healthcare Exchange (GHX)

NATICK, Mass., April 23 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that it has been named U.S. Healthcare Supplier of the Year in the GHXcellence Awards for achievements in improving supply chain performance. The award recognizes Boston Scientific's successful use of electronic transactions to improve supply chain efficiency for customers and suppliers.

The annual awards were granted by GHX based on application of the following criteria to an organization's performance during the 2007 calendar year:

-- Increased use of e-commerce solutions throughout the healthcare supply chain -- Number of trading partners with whom they conduct e-commerce -- Percentage of orders transacted electronically -- Percentage of invoices transacted electronically -- Reduction in order and invoice discrepancies and errors

Boston Scientific has implemented numerous e-commerce transaction options, including electronic order placement, electronic invoicing, advance shipping notices and electronic catalogs. Currently, more than 80 percent of the Company's domestic customers employ Electronic Data Interchange (EDI) to facilitate business transactions. EDI is the electronic transfer of structured data in a standard format between businesses, organizations or other groups.

"This award acknowledges our commitment to the use of e-commerce to improve efficiency and reduce costs throughout the supply chain," said Paul LaViolette, Boston Scientific Chief Operating Officer. "Through process and software system improvements, we have been able to expand our electronic offerings and increase transaction efficiency and customer satisfaction."

"This year's GHXcellence Awards honor providers and suppliers that have taken steps to maximize utilization of e-commerce solutions across their organizations," said GHX President Bruce Johnson. "By optimizing business processes and the use of technology, they are demonstrating how healthcare organizations can lower costs and improve operational performance."

The award was presented by GHX on Friday, April 18, 2008 during a recognition ceremony in Chicago at the 8th Annual GHX Supply Chain Summit.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.

About GHX

GHX enables healthcare providers and suppliers in North America and Europe to reduce costs and improve margins by automating processes, reducing operating expenses and increasing knowledge-based decision making. Products and services include trading partner connectivity, order and contract management and validation, data synchronization, sales force automation and business intelligence. For more information, visit http://www.ghx.com/

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our supply chain management and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation Larry Neumann 508-650-8696 (office) Investor Relations Boston Scientific Corporation

Boston Scientific Corporation

CONTACT: Paul Donovan, Media Relations, 1-508-650-8541, or mobile,
1-508-667-5165; Larry Neumann, Investor Relations, 1-508-650-8696,
both of Boston Scientific Corporation

Web site: http://www.bostonscientific.com/
http://www.ghx.com/

Service to mankind or medicine for profit - c c

c c	Service to mankind or medicine for profit c c , China - 1 hour ago China attracts them with its sound infrastructure, low research cost and the huge number of patients suffering from chronic and infectious diseases. ...

Threat To Pharmaceutical Industry Support For University Research - Medical News Today (press release)

Threat To Pharmaceutical Industry Support For University Research Medical News Today (press release), UK - 13 hours ago The pharmaceutical industry has extensive collaborative research links with the UK university science base, but there are growing signs that it is under ...

Indevus to Announce Second Quarter Fiscal 2008 Financial Results on Wednesday, April 30, 2008 Company to Conduct Conference Call and Webcast

LEXINGTON, Mass., April 23 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. will announce its second quarter fiscal 2008 financial results in a press release to be issued before market open on Wednesday, April 30, 2008. The Company will host a conference call and webcast to discuss these results at 9:00 AM eastern time on Wednesday, April 30, 2008.

The live call may be accessed by dialing 888-713-4218 from the U.S. and Canada, and 617-213-4870 from international locations. The participant passcode is 85206063. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PKMQDNKX4. Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection. A replay of the call will be available beginning at 11:00 AM on April 30, 2008 and lasting until 12:00 AM on May 28, 2008. To access the replay, please dial 888-286-8010 from the U.S. and Canada, and 617-801-6888 from international locations, using the passcode 23855950.

The press release and the live webcast will be accessible by visiting the Investors section of the Company's website, http://www.indevus.com/. An archived version of the call will be accessible at the same web address for 30 days following the live call.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA XR(TM) and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Indevus Pharmaceuticals, Inc.

CONTACT: Michael W. Rogers, Executive Vice President and CFO,
1-781-861-8444, or Brooke D. Wagner, VP, Corp. Communications,
1-781-402-3410, both of Indevus Pharmaceuticals, Inc.

Web site: http://www.indevus.com/

Other News To Note - TMCnet

Other News To Note TMCnet - 21 minutes ago Under the terms, the two companies are working to identify small-molecule therapeutics with the potential to treat several diseases, including Type II ...

G & S Minerals Announces Submission of Company Information and ... - Market Wire (press release)

G & S Minerals Announces Submission of Company Information and ... Market Wire (press release) - 2 hours ago Under the Pink Sheets OTC market tier system, the Company is currently categorized as "Caveat Emptor," reflecting a public interest concern about the ...

eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008

PHILADELPHIA, April 23 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it will release its 2008 first quarter results for the period ended March 31, 2008 on Monday, May 5,2008 after the market closes. After the release, the Company will host a conference call at 5:00 PM ET later that day.

For the conference call interested participants should dial 800-322-5044 when calling within the United States or 617-614-4927 when calling internationally along with pass code 13961971. There will be a playback available as well. To listen to the playback, please call 888-286-8010 when calling within the United States or 617-801-6888 when calling internationally. Please use pass code 12540628 for the replay.

This call is being webcast by Thomson Financial and can be accessed at eRT's web site at http://www.ert.com/ . The webcast may also be accessed at Thomson's Institutional investor website at http://www.streetevents.com/. The webcast can be accessed for up to one year on either site.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/ ) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission.

Contact: Richard Baron Robert East eResearchTechnology, Inc. Westwicke Partners, LLC 215-282-5566 410-321-9652

eResearchTechnology, Inc.

CONTACT: Richard Baron of eResearchTechnology, Inc., 1-215-282-5566; or
Robert East of Westwicke Partners, LLC, 1-410-321-9562

Web site: http://www.ert.com/

Risk Management: Best Practices for Medical Device Profitability FDAnews and Industry Directions Launch New Study

FALLS CHURCH, Va. and CUMMAQUID, Mass., April 23 /PRNewswire-USNewswire/ -- FDAnews and Industry Directions Inc., in close association with research analysis partner Cambashi Ltd, today invited medical device manufacturers to respond to a new survey on current industry challenges and practices. The survey asks about company objectives, business processes and practices, information systems and applications, and performance.

The research team is seeking responses from all companies in the medical device industry -- of all sizes, all classes of devices, and in every geographic region. The initial online survey is open for industry response from now until early May. All responses will be aggregated to formulate report findings. Individual responses will remain strictly confidential.

The results of this survey will be released at the Fifth Annual Medical Device Quality Congress June 25-27 in Cambridge, MA in a special session on the research, Risk Management: Best Practices for Medical Device Profitability. This research ties in closely with this year's conference theme, Leading the Way to Better Performance With Quality Systems Compliance.

The study findings will be used by medical device manufacturers and others serving the industry to improve their performance and reduce business risk. The study will assess and identify opportunities for streamlining practices so manufacturers can achieve quality and regulatory compliance while increasing profit and growth.

The online survey is available at: http://www.surveymethods.com/EndUser.aspx?F4D0BCA5F6BEA6A6 or through http://www.fdanews.com/ or http://www.industrydirections.com/. The survey is open to medical device manufacturers of all sizes worldwide. All survey respondents will receive a copy of the public findings report when it is released.

The research has been sponsored by five co-sponsor companies -- all of whom are active in the Medical Device sector. The analysis will be completed by Cambashi Ltd. and the report will be prepared independently by Industry Directions, which retains full editorial control.

The five co-sponsor companies underwriting the effort provide deep and diverse expertise in medical devices practices and provide production, quality, compliance, document management, and enterprise software to the industry. These companies are working together to increase the medical device market's understanding of how to reduce risks and improve compliance and profitability. Research sponsors for the study are: Camstar Systems (http://www.camstar.com/ ), IBS America (http://www.ibs-us.com/), IQMS (http://www.iqms.com/), MasterControl (http://www.mastercontrol.com/) and Pilgrim Software (http://www.pilgrimsoftware.com/).

FDAnews

CONTACT: Matt Salt of FDAnews, 1-703-538-7600, msalt@fdanews.com; or
Julie Fraser of Industry Directions, 1-508-362-3480,
jfraser@industrydirections.com

Web Site: http://www.camstar.com/

Varian Medical Systems Announces Record Demand for New RapidArc(TM ... - Earthtimes

Varian Medical Systems Announces Record Demand for New RapidArc(TM ... Earthtimes, UK - 37 minutes ago The increased throughput on our most advanced treatment unit will allow the UAB Department of Radiation Oncology to offer image-guided intensity-modulated ... Varian Medical Systems Reports Strong Growth in Net Earnings ... Earthtimes all 7 news articles

Peasant food: Spicing up your diet with chili peppers - WalletPop

Peasant food: Spicing up your diet with chili peppers WalletPop, VA - 1 hour ago They contain an impressive array of vitamins and minerals, including Vitamins A, C, D, E, and B6, as well as considerable amounts of potassium, magnesium, ...

Signalife Awarded New U.S. Patent, 'System For, And Method Of, Monitoring Heartbeats Of A Patient'

GREENVILLE, S.C., April 23 /PRNewswire-FirstCall/ -- Signalife, Inc. has announced that the United States Patent and Trademark Office has awarded the Company a new and important patent entitled "System For, And Method Of, Monitoring Heartbeats Of A Patient". The patent, which covers 37 claims, will enhance the Company's ability to develop new proprietary products.

Patent attorneys from Fulwider & Patton supervised and executed the patent application along with Chief Technology Officer Budimir S. Drakulic -- the inventor of the patented technology. The new patent is owned by Signalife, Inc. In conjunction with the Patent Office's granting of the patent, the Company will now evaluate whether or not it will file a continuation or continuation-in-part application for the purpose of pursuing additional claim coverage in the technology that may have occurred since the time of the original application.

Budimir S. Drakulic called the patent-issuance-development a "major milestone in the continued proliferation and protection of the Company's core technologies and products." Dr. Drakulic continued to say that issued patents together with significant patent portfolio already submitted to the United States Patent Office and two Frost & Sullivan technology awards represent major achievements for a young medical device company.

The Company currently has several additional patents pending before the United States Patent and Trademark Office covering a wide array of cardiac technologies and products. Dr. Drakulic stated that he is "confident the Company will continue to be successful in obtaining approvals for pending patents of its technologies and products."

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com/. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state or governmental or international regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain import and export capabilities in the various countries containing buyers and resellers and hospitals and clinics and doctors for the Signalife devices, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.

Signalife, Inc.

CONTACT: Dr. Budimir Drakulic, CTO, Signalife, Inc., 1-864-233-2300

Web site: http://www.signalife.com/

Blumenthal gripes to state lawmakers about pharmaceutical industry - Legal News Line

Blumenthal gripes to state lawmakers about pharmaceutical industry Legal News Line, DC - Apr 22, 2008 The International Federation of Pharmaceutical Manufacturers and Associations passed measures last year that prevent any of its members from paying for ...

BD Announces Results for Second Fiscal Quarter - Earthtimes

BD Announces Results for Second Fiscal Quarter Earthtimes, UK - 9 hours ago BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new ...

Increase in Travel to China Creating New Health and Security Risks New China White Paper from MEDEX Global Group Offers Tips for Travelers

BALTIMORE, April 23 /PRNewswire/ -- Infectious disease, poor sanitary conditions and substandard healthcare are among the serious medical concerns found in China, according to a new white paper recently released by MEDEX Global Group, a worldwide provider of international travel, security and medical insurance.

"This year, China expects 150 million foreign tourists, which is a 14 percent increase over 2007," said Bruce Kirby, CEO of MEDEX Global Group. "This paper is intended to prepare the rapidly growing number of travelers for the unexpected by arming them with well-documented, critical health information."

"What You Should Know Before Traveling Abroad: Health and Security Risks in China" captures the results from a series of 300-point, onsite evaluations of medical care and health facilities throughout China. To compile the evaluation, MEDEX experts examined a variety of factors including the country's quality of healthcare, blood supply and disease risks. The full report is available for free download at http://www.medexassist.com/travelguides.

Overall, on a scale of 1-5, with 5 being the lowest rating, MEDEX gave China a score of "4". Training for doctors and nurses may not be up to international standards, and in rural areas of China, medical care is more rudimentary than in urban areas. Hospitals may not have modern equipment or even plumbing. In fact, only 28% of the population in rural China has access to adequate sanitation facilities.

The MEDEX report offers a number of health and medical-related tips for travelers:

-- In case of emergency in China, private clinics are recommended over public hospitals. Public hospitals are overcrowded, patients will likely wait hours and most often payment is expected in cash and prior to admission. Foreign health insurance plans are not accepted. -- Ambulances are not reliable in an emergency. Private transportation, even in an emergency, is often the fastest alternative. -- Blood supply in China is not safe. The AIDS virus is a significant concern in China and there is a risk of exposure to unsafe blood and blood products. -- Six to eight weeks before leaving for China, visit a travel clinic to receive necessary vaccinations, including: Hepatitis A, Hepatitis B, Typhoid, Japanese Encephalitis, Rabies and the flu vaccine.

Upon entering China, all visitors are required to complete a Health Declaration Form to notify authorities of any existing health conditions. Travelers with certain infectious diseases may not be permitted to enter the country.

Additional details and rankings are included as part of MEDEX 360m Global Medical Monitor reports, a medical information service created in partnership with Harvard Medical International. It provides the most robust and comprehensive online medical resource available on China as well as 236 other countries and territories.

ABOUT MEDEX Global Group

MEDEX Global Group has been assisting travelers with medical and security emergencies for more than 30 years, providing international travel, security and medical support for corporations, government and humanitarian organizations, and leisure travelers. MEDEX services include everything from pre-trip intelligence and contingency planning to real-time medical case monitoring, complex emergency evacuations and virtually every contingency in between. The MEDEX Emergency Response Center handles nearly 30,000 cases a year in over 200 countries. For more information, visit http://www.medexassist.com/.

MEDEX Global Group

CONTACT: Josianne Pennington of MEDEX Global Group, 1-410-453-6364,
jpennington@medexassist.com; or Gillian Pommerehn, 1-410-626-0805,
gpommerehn@crosbymarketing.com, for MEDEX Global Group

Web site: http://www.medexassist.com/

Perrigo CEO: Health care industry can depend on generics to ... - MLive.com

MLive.com

Perrigo CEO: Health care industry can depend on generics to ... MLive.com, MI - 2 hours ago The pharmaceutical industry faces major challenges related to the impending expiration of key patents for drugs such as Pfizer's Lipitor and Eli Lilly's ...

Lupin enters gynaecology segment - Economic Times

Lupin enters gynaecology segment Economic Times, India - 2 hours ago "We will concentrate on chronic therapeutic areas such as cardiology, neurology, oncology and diabetology. Now we have entered the gynaecology segment," ...

Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)

CAMBRIDGE, Mass., and MILAN, Italy, April 23 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced preclinical data from the company's polymerase and protease inhibitor programs for the treatment of hepatitis C. These data are being presented at the Annual Meeting of the European Association for the Study of the Liver (EASL) being held this week in Milan, Italy.

Second-Generation Nucleoside Polymerase Inhibitor Program

IDX184 is a nucleotide prodrug derived from Idenix's proprietary liver- targeting technology. Results from in vitro and in vivo preclinical studies confirm that this technology preferentially activates IDX184 in the liver, potentially enhancing the antiviral activity of the drug and limiting systemic side effects. In an HCV replicon model, IDX184 exhibited 10 times greater potency than the first-generation HCV nucleoside clinical drug candidates currently in development. In HCV genotype-1 infected chimpanzees, once-daily oral administration of 10 mg/kg of IDX184 resulted in a mean viral load reduction of 2.3 log10 (n=5) after four days of dosing. No toxicities, including gastrointestinal or hematological, or abnormal blood chemistry were observed at oral doses greater than or equal to 600 mg/kg/day in a supporting seven-day toxicology study in cynomolgus monkeys.

IDX184 demonstrated additive antiviral activity in the HCV replicon in combination with HCV protease inhibitors and interferon and synergistic activity in combination with ribavirin. IDX184 also remained fully active in vitro against HCV containing known protease and non-nucleoside inhibitor drug resistance mutations.

Data from this program are being presented by David Standring, Ph.D., executive vice president, biology, Idenix Pharmaceuticals, in an oral presentation session at 5:30 p.m. CET on Friday, April 25, 2008, and by Erika Cretton-Scott, Ph.D., director, preclinical pharmacology at Idenix Pharmaceuticals, in a poster session beginning on Thursday, April 24, 2008.

Novel Macrocyclic Protease Inhibitor Program

Based on two novel macrocyclic scaffolds, Idenix has discovered compounds that demonstrated potency with subnanomolar antiviral activity against the HCV genotype 1b NS3/4A protease target and single nanomolar activity in the HCV replicon. These compounds also displayed high selectivity in vitro with no inhibition of selected human cellular proteases. In vitro, the Idenix protease inhibitors exhibited antiviral activity against certain HCV resistant mutants associated with first-generation protease inhibitors currently in clinical development. Pharmacokinetic studies demonstrated adequate oral bioavailability and sustained liver concentrations suggesting the potential for once-daily or twice-daily dosing. Data from this program are being presented by Dr. Standring in an oral presentation session at 6:15 p.m. CET on Thursday, April 24, 2008.

"The preclinical profiles emerging in our HCV nucleoside and protease inhibitor programs are very encouraging when compared to first-generation drug candidates from both of these drug classes," said David Standring, Ph.D., executive vice president, biology, of Idenix. "We plan to have product candidates from both of these programs in clinical development within the next 12 months with the goal to evaluate our own novel combinations thereafter."

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com/.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by the use of forward-looking terminology such as "could," "may," "plans," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs in hepatitis C, or any potential pipeline candidates for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, pre-clinical studies and/or clinical trials, including additional data relating to the ongoing pre-clinical studies and/or clinical trials evaluating its product candidates, including IDX 184 and novel protease inhibitors; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Idenix Pharmaceuticals Contact:

Teri Dahlman (617) 995-9905

Idenix Pharmaceuticals, Inc.

CONTACT: Teri Dahlman of Idenix Pharmaceuticals, Inc., 1-617-995-9905

Web site: http://www.idenix.com/

Threat To Pharmaceutical Industry Support For University Research - Medical News Today (press release)

InTheNews.co.uk

Threat To Pharmaceutical Industry Support For University Research Medical News Today (press release), UK - 1 hour ago The pharmaceutical industry has extensive collaborative research links with the UK university science base, but there are growing signs that it is under ... University science ties 'weakening' The Press Association ABPI warns UK's scientific research is suffering InTheNews.co.uk all 3 news articles

Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer Avastin Used in Combination with Taxol and Paraplatin Will Become the Clinical Gold Stand

WALTHAM, Mass., April 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed oncologists say that a therapy's effect on overall survival is the attribute that most influences their prescribing decisions in advanced ovarian cancer. Clinical data and expert opinion show that Roche/Genentech/Chugai's Avastin (bevacizumab) plus the regimen of paclitaxel (Bristol-Myers Squibb's Taxol, generics) and carboplatin (Bristol- Myers Squibb's Paraplatin, generics) has advantages in this attribute over the combination of paclitaxel/carboplatin, the current sales leader in ovarian cancer treatment.

The new report entitled Ovarian Cancer (Advanced): Therapies Must Increase Survival over Paclitaxel/Carboplatin to Successfully Enter this Generic Market finds that, according surveyed oncologists, a drug that offers improved median overall survival compared with paclitaxel/carboplatin would earn a 50 percent patient share in the ovarian cancer market. Surveyed oncologists indicated that they would prescribe Avastin plus paclitaxel/carboplatin to 29 percent of their patients with advanced ovarian cancer. As a result, Avastin plus paclitaxel/carboplatin will earn a 22 percent patient share in the U.S. advanced ovarian cancer market in 2016.

The report also finds that Avastin plus paclitaxel/carboplatin will earn the clinical gold-standard status for treatment of advanced ovarian cancer in 2011, following its approval for the indication in 2010. Surveyed oncologists indicated that Avastin plus paclitaxel/carboplatin has competitive advantages in efficacy over paclitaxel/carboplatin, the current gold standard.

"Avastin plus paclitaxel/carboplatin has the same delivery attributes and only marginally different safety attributes when compared with paclitaxel/carboplatin," said Jenna Avent, analyst at Decision Resources. "However, the regimen of Avastin plus paclitaxel/carboplatin has better efficacy when compared to the current gold standard, paclitaxel/carboplatin, and oncologists rate efficacy as the most important parameter in the treatment of advanced ovarian cancer."

About the Report

Ovarian Cancer (Advanced): Therapies Must Increase Survival over Paclitaxel/Carboplatin to Successfully Enter this Generic Market is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 emarshall@dresources.com

Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, 1-781-296-2563,
emarshall@dresources.com

Web site: http://www.decisionresources.com/

Unigene Joint Venture Breaks Ground for Global Biotechnology Park ... - Business Wire (press release)

Unigene Joint Venture Breaks Ground for Global Biotechnology Park ... Business Wire (press release), CA - 12 minutes ago It is one of the worlda s leading producers of vitamins and antibiotics, producing 30000 tons of vitamin C and 10000 tons of penicillin. ...

Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial More than 90% of CIA patients treated with PBI-1402 did not require blood transfusion.

MONTREAL, April 23 /PRNewswire-FirstCall/ -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announces that oral PBI-1402 demonstrates significant activity in patients with chemotherapy-induced anemia ("CIA"), and reduces the need for red blood cell ("RBC") transfusion.

Only 2 patients out of 28 (7%) treated with PBI-1402 required a RBC transfusion, a response rate greater than 90% with regards to this clinical objective. In the March 13, 2008 FDA briefing document, the Oncologic Drugs Advisory Committee emphasizes that the primary objective of treating CIA patients with erythropoiesis-stimulating agents ("ESAs") as being the ability to reduce the need for RBC transfusion. The Advisory Committee cites that approximately 50% of anemic patients receiving chemotherapy required RBC transfusion, and 20%-25% of patients treated with ESAs still required RBC transfusions.

"These results are very exciting and meet the primary objective that formed the basis for FDA approval of other ESAs in CIA patients," states Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc. "This new encouraging data further supports the potential role PBI-1402 could play in the management of anemia in patients with cancer," added Mr. Laurin.

CIA patients enrolled in the study received a once daily oral dose of PBI-1402 during a period of eight weeks while undergoing their normal course of chemotherapy. All patients enrolled have completed the PBI-1402 treatment period.

About PBI-1402

PBI-1402 is an orally active compound being developed to treat different types of anemia, such as CIA. PBI-1402 has a distinct mechanism of action and does not act through EPO receptor. ProMetic has recently expanded its clinical program for PBI-1402 into the treatment of anemia in patients with myelodysplastic syndrome ("MDS"), a condition often referred to as "pre-leukemia". In addition, a new Phase II study in patients with anemia resulting from chronic kidney disease has been scheduled.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (http://www.prometic.com/) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand (TM) enabling technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2006, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

PROMETIC LIFE SCIENCES INC.

CONTACT: Company Inquiries: Pierre Laurin, President and CEO, ProMetic
Life Sciences Inc., (514) 341-2115, p.laurin@prometic.com; Anne Leduc,
Manager, Investor Relations & Communications, ProMetic Life Sciences Inc.,
(514) 341-2115, a.leduc@prometic.com; Dominic Sicotte, Echoes Financial
Network Inc., (514) 842-9551, dsicotte@echoesfinancial.com; Media Relations:
Jules Abraham, Lippert/Heilshorn & Associates, (212) 838-3777,
Jabraham@lhai.com

Startech Environmental to Have Three Plasma Converters in Former ... - Earthtimes

Startech Environmental to Have Three Plasma Converters in Former ... Earthtimes, UK - Apr 21, 2008 ... Plasma Converters Systems, purchased last year from the Company, in an existing, former pharmaceutical-industry-facility also located in Puerto Rico. ...

Cytokinetics to Announce First Quarter Results on April 29, 2008 - CNNMoney.com

Cytokinetics to Announce First Quarter Results on April 29, 2008 CNNMoney.com - 12 hours ago GSK began a Phase I clinical trial with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potential drug candidate directed ...